Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
G Chir ; 40(6): 544-550, 2019.
Article in English | MEDLINE | ID: mdl-32007118

ABSTRACT

BACKGROUND: Undifferentiated pleomorphic sarcoma (UPS) of the breast is an extremely rare, but aggressive subtype of sarcoma that can develop in radiotherapy (RT)-treated breast cancer patients. Due to the low incidence, there are many uncertainties regarding the adequate management of these tumors. We present a rare case of radiation-induced UPS in a 63-year-old woman who had undergone breast conserving therapy for invasive ductal carcinoma of the left breast, six years prior to presentation. CASE PRESENTATION: A 63-year-old woman presented with a rapidly growing left breast mass. She had been diagnosed with invasive ductal carcinoma of the left breast for which she underwent a left upper outer quadrantectomy and ipsilateral axillary dissection followed by RT, six years previously. During her routine oncologic follow-up, the mammography revealed a dense, nodular opacity with microcalcifications. The breast ultrasound (US) confirmed the presence of the nodule. US-guided fine needle aspiration biopsy was performed and the diagnosis of UPS was made, the reason for which the patient underwent wide local excision of the left breast. CONCLUSION: The diagnosis of RT-induced UPS is challenging and often missed due to the low incidence, long latency period, unspecific imaging findings, and difficulties in clinical and histological detection of these lesions. These tumors should be considered in differential diagnoses of rapidly-growing breast masses in previously RT-treated breast cancer patients, as they can mimic the local recurrence of the primary tumor. Since the prevalence of breast-conserving surgery followed by RT has been increasing, the careful monitoring of at risk patients is of utmost importance, as UPSs are highly aggressive tumors associated with very poor outcomes.


Subject(s)
Breast Neoplasms/etiology , Carcinoma, Ductal, Breast/radiotherapy , Mastectomy, Segmental , Neoplasms, Radiation-Induced/etiology , Radiotherapy, High-Energy/adverse effects , Sarcoma/etiology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Ductal, Breast/surgery , Chemotherapy, Adjuvant , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Diagnosis, Differential , Epirubicin/administration & dosage , Female , Humans , Letrozole/administration & dosage , Mastectomy , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Neoplasms, Radiation-Induced/diagnosis , Neoplasms, Radiation-Induced/pathology , Neoplasms, Radiation-Induced/therapy , Photons , Sarcoma/diagnosis , Sarcoma/pathology , Sarcoma/therapy , Ultrasonography, Mammary
2.
Ophthalmic Res ; 37(2): 72-82, 2005.
Article in English | MEDLINE | ID: mdl-15746562

ABSTRACT

BACKGROUND: In hereditary retinal degeneration, microglia cells become activated, migrate through the outer nuclear layer (ONL) and accumulate in the subretinal space. Although this inflammatory process is not likely to be responsible for the onset of photoreceptor apoptosis, cytotoxic substances secreted by activated microglia could potentially accelerate and perpetuate the degenerative process. Anti-inflammatory drugs have been shown to modulate the microglia response in neurodegenerative disorders and potentially ameliorate the disease progression in various animal model systems. In this study we wanted to test the impact of the most commonly used anti-inflammatory drugs (acetylsalicylate and prednisolone) on the microglia activation pattern, the rate of caspase-3-dependent photoreceptor apoptosis and the course of the degeneration in the retinal degeneration slow (rds) mouse retina. METHODS: 169 pigmented rds mice and 30 CBA wild-type mice were used for this study. The treatment groups were injected daily with either acetylsalicylate (200 mg/kg) or prednisolone (2 mg/kg) i.p. from day 0 up to 3 months. Animals were sacrificed at days 10, 14, 16, 18, 20, 30, 40, 60 and 90. Cryoprotected frozen sections were immunostained with F4/80 and cleaved caspase-3 antibodies. The main outcome measures were the total microglia count in the subretinal space, the total cleaved caspase-3-positive cells in the ONL and the averaged number of photoreceptor rows in the midperipheral retina. RESULTS: Neither acetylsalicylate nor prednisolone reduced subretinal microglia accumulation in the rds mouse degeneration model. Moreover, they aggravated migration and accumulation in the early time course. The apoptotic cascade started earlier and was more pronounced in both treatment groups compared to the control group. The pace of retinal degeneration was not reduced in the treatment groups compared to the untreated control. In contrast, acetylsalicylate did significantly accelerate the photoreceptor cell degeneration in comparison to the prednisolone (p < 0.001) and to the control group (p < 0.001). CONCLUSIONS: Acetylsalicylate and prednisolone do not decrease the microglia response in the rds mouse and are not neuroprotective. More research is needed to clarify the molecular mechanisms which lead to photoreceptor cell death and to elucidate the complex role of microglia in inherited retinal degeneration.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Glucocorticoids/pharmacology , Microglia/drug effects , Retinal Degeneration/metabolism , Animals , Antigens, Differentiation/metabolism , Apoptosis/drug effects , Aspirin/pharmacology , Caspase 3 , Caspases/metabolism , Cell Count , Cell Movement/drug effects , Immunoenzyme Techniques , Injections, Intraperitoneal , Mice , Mice, Inbred CBA , Mice, Mutant Strains , Microglia/pathology , Microscopy, Confocal , Photoreceptor Cells, Vertebrate/metabolism , Photoreceptor Cells, Vertebrate/pathology , Prednisolone/pharmacology , Retinal Degeneration/pathology
3.
Tumori ; 67(3): 183-9, 1981.
Article in English | MEDLINE | ID: mdl-7281237

ABSTRACT

It has been reported that cytocidal activity of light-activated hematoporphyrin (HPD) within the cells might be exploited in the therapy of experimental and human cancer. As part of a project from this laboratory aimed to study some major biologic features of HPD, it was found that [3H]thymidine incorporation in tumor cells was highly inhibited as a consequence of HPD treatment. HPD-mediated inhibition, obtained by a treatment either in vitro or in vivo, was long lasting and independent of light activation. Cellular DNA synthesis was inhibited by non toxic doses of HPD which were not influential either cell viability or cell oncogenicity. In preliminary studies, HPD-treated cells accumulated in the G1 phase of the cell cycle as detected by cytofluorometric analysis. This finding is in keeping with a likely inhibition exerted in late G1 or at the beginning of the S phase of cell the cycle and might exclude a direct damage of the DNA synthetic machinery. Definitive loss of cell viability and cellular DNA inhibition was obtained immediately after the exposure of HPD-treated cells to He-Ne laser light. HPD-mediated cell lysis was dose dependent and in the other of magnitude of cytocidal doses in different cell systems. HPD antileukemic activity or HPD interactions with chemotherapeutic drugs was ruled out in L1210 leukemic mice.


Subject(s)
DNA, Neoplasm/biosynthesis , Hematoporphyrins/pharmacology , Leukemia L1210/drug therapy , Animals , Antineoplastic Agents/therapeutic use , Cell Cycle , Cell Survival , Female , Lasers , Light , Male , Mice , Mice, Inbred DBA
SELECTION OF CITATIONS
SEARCH DETAIL